# Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

> **NCT03048942** · PHASE2 · UNKNOWN · sponsor: **University Hospitals Bristol and Weston NHS Foundation Trust** · enrollment: 160 (estimated)

## Conditions studied

- HER2 Negative Metastatic Breast Cancer

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03048942
- **Lead sponsor:** University Hospitals Bristol and Weston NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048942, "Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03048942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*